5608 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Solit
    Solit
  4. Morris
    Morris
  5. Bajorin
    Bajorin
  6. Rosenberg
    Rosenberg
  7. Berger
    Berger
  8. Iyer
    Iyer
  9. Reuter
    Reuter
  10. Feldman
    Feldman

Groups

  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)
  7. Surgery (1000)
  8. Epidemiology and Biostatistics (864)
  9. Survivorship Research (773)
  10. Urology (769)
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The brief pain inventory and its "pain at its worst in the last 24 hours" item: Clinical trial endpoint considerations
    Journal Article

    Atkinson, T. M.; Mendoza, T. R.; Sit, L.; Passik, S.; Scher, H. I.; Cleeland, C.; Basch, E.
    Pain Medicine (2010)

    Fulltext@MSK | Save
  • A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis
    Journal Article

    Alimonti, A.; Nardella, C.; Chen, Z.; Clohessy, J. G.; Carracedo, A.; Trotman, L. C.; Cheng, K.; Varmeh, S.; Kozma, S. C.; Thomas, G.; more...
    Journal of Clinical Investigation (2010)

    Fulltext@MSK | Save
  • Melanoma-specific targeted therapies
    Book Section

    Chapman, P. B.; Solit, D. B.; Flaherty, K. T.
    In Balch, C. M.; Houghton, A. N.; Sober, A. J.; Soong, S. J.; Atkins, M. B.; Thompson, J. F (Eds.) Cutaneous Melanoma. 5th ed (2009)

    Fulltext@MSK | Save
  • Evaluation and treatment of prostate and genitourinary cancer
    Book Section

    Morozov, A.; Slovin, S. F.
    In Stubblefield, M. D.; O'Dell, M. W. (Eds.) Cancer Rehabilitation: Principles and Practice. 1st ed (2009)

    Fulltext@MSK | Save
  • Cytokine changes in castrate metastatic prostate cancer (CPMC) patients (pts) treated with ipilimumab (Ipi)
    Meeting Abstract

    Yuan, J.; Orlandi, F.; Jefferson, M.; Li, H.; Gallardo, H.; Ku, G.; Wolchok, J.; Scher, H.; Allison, J.; Slovin, S. F.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Initial phase II experience of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Slovin, S. F.; Beer, T. M.; Higano, C. S.; Tejwani, S.; Hamid, O.; Picus, J.; Harzstark, A.; Scher, H. I.; Lan, Z.; Lowy, I.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Prostate Cancer Clinical Trials Consortium: A multicenter mechanism for the rapid design, development, and implementation of early phase clinical trials
    Meeting Abstract

    Vinson, J.; Mathew, P.; Beer, T. M.; Carducci, M. A.; Oh, W.; Small, E.; Wilding, G.; Higano, C.; Hussain, M.; Scher, H. I.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Antitumor activity of MDV3100 in a phase I/II study of castration-resistant prostate cancer (CRPC)
    Meeting Abstract

    Scher, H. I.; Beer, T. M.; Higano, C. S.; Taplin, M.; Efstathiou, E.; Anand, A.; Hung, D.; Hirmand, M.; Fleisher, M.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • A phase Ib trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in combination with docetaxel
    Meeting Abstract

    Riely, G. J.; Stoller, R.; Egorin, M.; Solit, D.; Dunbar, J.; Savage, A.; Walker, J.; Grayzel, D.; Ross, R.; Weiss, G. J.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Diastolic blood pressure (dBP) and pharmacokinetics (PK) as predictors of axitinib efficacy in metastatic renal cell cancer (mRCC)
    Meeting Abstract

    Rixe, O.; Dutcher, J.; Motzer, R.; Wilding, G.; Stadler, W. M.; Garrett, M.; Pithavala, Y.; Kim, S.; Tarazi, J.; Rini, B. I.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save